SCHEMBL5510203

SCHEMBL5510203

CCOc1cc2c(cc1OC)C(c1ccc(-n3ccnc3)cc1)=N[C@H]1CC[C@H](O)C[C@@H]21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.48
PDE4B Q07343 3/20 0.48
PDE4A P27815 3/20 0.48
PDE4C Q08493 2/20 0.48
MCHR1 Q99705 1/20 0.37
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
CYP19A1 P11511 3/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2D6 P10635 3/20 0.35
CYP2C9 P11712 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP3A4 P08684 1/20 0.35
ESR1 P03372 2/20 0.33
ESR2 Q92731 1/20 0.33
PDE3A Q14432 2/20 0.32
MEN1 O00255 1/20 0.32
CHRM1 P11229 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503762 1.00 PDE4D (0.48) PDE4DPDE4BPDE4APDE4CMCHR1
SCHEMBL5506282 1.00 PDE4D (0.48) PDE4DPDE4BPDE4APDE4CMCHR1
SCHEMBL5506883 0.91 PDE4D (0.42) PDE4DPDE4BPDE4APDE4CMCHR1
SCHEMBL1411087 0.90 PDE4D (0.45) PDE4DPDE4BPDE4APDE4CCYP1A2
SCHEMBL2266059 0.90 PDE4D (0.45) PDE4DPDE4BPDE4APDE4CCYP1A2
SCHEMBL18092833 0.90 PDE4D (0.45) PDE4DPDE4BPDE4APDE4CCYP1A2
Bromide SCHEMBL1411151 0.89 PDE4D (0.44) PDE4DPDE4BPDE4APDE4CCYP1A2
Oxalic Acid SCHEMBL1411367 0.86 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CFPR2
Sulfuric Acid SCHEMBL1411685 0.86 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CCYP1A2
SCHEMBL2265927 0.86 PDE4D (0.51) PDE4DPDE4BPDE4APDE4CPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors ATLANTA PHARMA AG (DE) 2007-08-16 US claimed
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors ATLANTA PHARMA AG (DE) 2007-08-16 US disclosed
EP-1812400-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2007-08-01 EP disclosed
WO-2005090311-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors PDE4A, PDE4B, PDE4C PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.